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Zein is a water-insoluble polymer from maize seeds that has been widely used to
produce carrier particles for the delivery of therapeutic molecules. We encapsulated a
recombinant model vaccine antigen in newly formed zein bodies in planta by generating
a fusion construct comprising the ectodomain of hemagglutinin subtype 5 and the
N-terminal part of γ-zein. The chimeric protein was transiently produced in tobacco
leaves, and H5-containing protein bodies (PBs) were used to immunize mice. An
immune response was achieved in all mice treated with H5-zein, even at low doses. The
fusion to zein markedly enhanced the IgG response compared the soluble H5 control,
and the effect was similar to a commercial adjuvant. The co-administration of adjuvants
with the H5-zein bodies did not enhance the immune response any further, suggesting
that the zein portion itself mediates an adjuvant effect. While the zein portion used
to induce protein body formation was only weakly immunogenic, our results indicate
that zein-induced PBs are promising production and delivery vehicles for subunit
vaccines.
Keywords: protein bodies, molecular farming, subcellular targeting, recombinant protein, recombinant vaccine
INTRODUCTION
Polymers are widely used as carrier biomaterials for the delivery of therapeutic molecules (Petros
and DeSimone, 2010). In particular, biopolymer-based nanoparticles have proven suitable for
clinical applications due to their biocompatibility and biodegradability (Panyam and Labhasetwar,
2003; Nitta and Numata, 2013). A variety of materials and preparation methods have been
developed for application-specific properties in terms of particle shape, surface charge, and surface
features (Petros and DeSimone, 2010). Among the protein-based biopolymers, those derived from
natural proteins such as silk, collagen, elastin, and fibronectin have been studied in detail (Ruszczak
and Friess, 2003; Daamen et al., 2007; Lammel et al., 2010; Nitta and Numata, 2013).
Zein, a protein-based polymer found in maize seeds, has been widely used as a carrier because
of favorable properties such as biocompatibility, insolubility and low water uptake, mechanical and
chemical stability, and its propensity to form coatings and microparticles (Liu et al., 2005; Lai and
Guo, 2011; Wang et al., 2011; Lau et al., 2013). Zein is also generally regarded as safe (GRAS) for
food use and resists digestion, making it particularly suitable as an encapsulation polymer for oral
drugs (Hurtado-Lopez and Murdan, 2006b; Gong et al., 2011; Lau et al., 2013; Zou and Gu, 2013;
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Ahmed et al., 2015). The intravenous delivery of drug-loaded
zein-based microparticles has also been investigated as a means to
achieve long-acting effects such as the slow and sustained release
of pharmaceutical compounds (Lai and Guo, 2011) and more
efficient drug delivery to cancer cells (Lin et al., 2011; Podaralla
et al., 2012; Lohcharoenkal et al., 2014). Zein-based microspheres
may also provide adjuvant effects when used as vaccine carriers
(Hurtado-Lopez and Murdan, 2006a).
The in vitro loading of zein-based microparticles with
drugs usually involves spray or freeze drying or liquid–liquid
dispersion methods (Zhong and Jin, 2009; Podaralla and
Perumal, 2010; Podaralla et al., 2012; Zou and Gu, 2013). These
technical processes are expensive and can affect the activity
of the encapsulated agent, e.g., the high temperatures required
for spray drying are incompatible with many pharmaceutical
proteins.
It is therefore appealing to use plants to achieve
microencapsulation in vivo by directly incorporating
recombinant proteins into naturally occurring protein storage
organelles such as zein bodies (Hofbauer and Stoger, 2013).
Endogenous protein storage organelles are usually found in
plant seeds, and zein-like prolamins are characteristic features of
cereal endosperm cells. In production systems based on cereal
seeds, the recombinant protein is often targeted to accumulate in
prolamin-containing storage organelles that provide a protective
environment, even offering some resistance against proteolytic
digestion in simulated gastric fluids (Takaiwa et al., 2015).
Instead of using the natural prolamin bodies that are formed
in rice, wheat, maize or barley endosperm, it is also possible
to fuse the recombinant protein to assembly sequences that
induce analogous structures in tissues such as leaves, which
usually lack protein storage organelles. This ectopic protein
body technology bypasses the longer generation time required to
produce cereal seeds while still offering the advantages of natural
bioencapsulation. Sequences that share the ability to trigger the
formation of ectopic protein bodies (PBs) include those derived
from cereal prolamins, synthetic elastin-like peptides (ELPs) and
fungal hydrophobins (Floss et al., 2008; Conley et al., 2009;
Torrent et al., 2009b; Gutierrez et al., 2013; Shigemitsu et al.,
2013).
One of the most widely used assembly sequences comprises
the N-terminal part of the mature 27 kD γ-zein protein, a
member of the major prolamin-type storage protein family
in maize (Shewry and Halford, 2002). Unlike other assembly
sequences, it not only induces the formation of PBs but also acts
as a retention sequence that stops fusion proteins from leaving
the endoplasmic reticulum (ER). Consequently, the induced PBs
bud from the ER as distinct round structures, underscoring the
intrinsic compartment-forming properties of the zein sequence
in the absence of tissue-specific factors (Mainieri et al., 2004;
Llop-Tous et al., 2010). The N-terminal sequence of the 27 kD
γ-zein protein comprises two cysteine residues downstream
of the signal peptide, a repeated proline-rich domain forming
an amphipathic helix, and a third section that includes four
additional cysteine residues (Geli et al., 1994). Several reports
have confirmed that zein-derived sequences induce ectopic PBs
when appended to either the N-terminus or the C-terminus
of diverse recombinant proteins, including phaseolin (Mainieri
et al., 2004), enhanced cyan fluorescent protein (Llop-Tous et al.,
2010), xylanase (Llop-Tous et al., 2011), DsRed (Joseph et al.,
2012), and the Human papillomavirus E7 protein (Whitehead
et al., 2014). Moreover, the ability to induce PBs appears to be
almost entirely intrinsic and independent of other host-specific
factors, thus allowing the formation of ectopic PBs in fungal,
insect and mammalian cells (Torrent et al., 2009a), and the
budding of PBs from ectopic membranes such as the plastid
envelope, when combined with alternative subcellular targeting
strategies (Hofbauer et al., 2014).
Hemagglutinin is an abundant type I integral membrane
glycoprotein found on the envelope of influenza viruses and it
has been widely used in influenza vaccine development and as
a model antigen. The precursor protein HA0 yields two chains,
i.e., HA1 (∼36 kDa) and HA2 (∼28 kDa), following cleavage
at the motif Q/E-X-R. Infectivity requires both chains to be
glycosylated, and also relies on the cleavage of hemagglutinin by
a protease at multiple arginine residues. (Klenk and Garten, 1994;
Hulse et al., 2004). The cleavage products are then covalently
linked by a disulfide bond and these HA1/HA2 units form non-
covalent homotrimers (Wiley et al., 1977).
A transmembrane domain is found near the C-terminus of
HA2. The three-dimensional structure of hemagglutinin reveals
two domains: a stem, responsible for membrane anchoring (part
of HA1 and all of HA2), and a globular head (only HA1),
bearing the sialic acid receptor binding domains (RBDs) (Wilson
et al., 1981). In this study we generated a fusion construct
comprising the ectodomain of hemagglutinin subtype 5 and
the N-terminal part of γ-zein (amino acids 4–93) in order to
induce the storage of the recombinant fusion protein inside newly
formed PBs. The chimeric protein was transiently produced in
tobacco leaves and H5-containing PBs were used to immunize
mice. The resulting immune response was compared to that of
control groups administered with the soluble H5 antigen, with or
without adjuvant.
MATERIALS AND METHODS
Vector Constructs
All cloning steps were carried out using the binary vector
pTRA, a derivative of pPAM (GenBank AY027531). The sequence
corresponding to the H5 ectodomain (amino acids 17–520)
of hemagglutinin from the A/Hatay/2004/(H5N1) influenza
strain (GenBank Q5QQ29) was amplified as described (Phan
et al., 2014) and a plant codon-optimized signal peptide
sequence derived from a murine antibody was added to the
N-terminus to direct the protein into the secretory pathway
(Vaquero et al., 1999). Amino acids 4–93 of the mature 27 kD
γ-zein protein (lacking the signal peptide) were joined to the
C-terminus via a (GGGS)2 linker as previously described for
the phaseolin fusion construct zeolin (Mainieri et al., 2004).
A His6-tag was added to the C-terminus for detection. The
final expression vector “H5-Zein” was produced by transferring
this coding sequence to the pTRA vector between the Tobacco
etch virus (TEV) 5′-untranslated region and the Cauliflower
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mosaic virus (CaMV) 35S terminator. The expression construct
was thus placed under the control of the CaMV 35S promoter
with a duplicated transcriptional enhancer. An analogous
construct comprising only the H5 ectodomain, a His6-tag and a
C-terminal KDEL sequence was used to produce the soluble H5
antigen.
Plant Material
Tobacco (Nicotiana benthamiana) plants were cultivated in soil
in a growth chamber with a 16-h photoperiod, 26/16◦C day/night
temperatures and 70% relative humidity for 2 months.
Agroinfiltration of Tobacco Leaves
The expression constructs were transferred by electroporation
into competent Agrobacterium tumefaciens (GV3101) cells. The
bacteria were kept as a glycerol stock and used to inoculate
5-ml aliquots of YEB medium containing 25 mg/l kanamycin,
25 mg/l rifampicin, and 50 mg/l carbenicillin. The cultures
were incubated for 2 days at 28◦C, shaking at 180 rpm. Each
culture was mixed 1:1 with a culture containing a silencing
inhibitor (HcPro) before adjusting with 2x infiltration medium
(100 g/l sucrose, 3.6 g/l glucose, 8.6 g/l MS salts, pH 5.6)
to an OD600 of ∼1.0. After adding 200 µM acetosyringone,
N. benthamiana leaves were infiltrated using a syringe (for small-
scale expression) or vacuum (for large-scale expression). Young
plants were completely submerged in the suspension and vacuum
was applied for 2 min. The infiltrated leaves were harvested 7 days
post-infiltration (DPI).
Protein Purification
Soluble H5: Immobilized Metal Affinity
Chromatography (IMAC)
Frozen leaf powder was mixed at a ratio of 1:2 (w/w) with cold
lysis buffer (50 mM sodium phosphate buffer, pH 8.0, 300 mM
NaCl, 5 mM imidazole, 0.5 mM PMSF) and sonicated briefly to
induce further cell lysis. After 2 h, the suspension was centrifuged
at 9000 rpm for 20 min and the supernatant was passed through
a 1-µm filter. The pH was re-adjusted to 8.0 and the suspension
was centrifuged as above. The supernatant was passed through a
0.45-µm filter before mixing with Ni-IDA IMAC resin (BioRad,
Munich, Germany). Approximately 2 ml of 50% resin suspension
was added per 50 ml supernatant. After incubation for 1 h, the
resin was loaded onto a column and washed with eight volumes
of wash buffer (50 mM sodium phosphate buffer, pH 8.0, 300 mM
NaCl, 10 mM imidazole). The protein was eluted with elution
buffer (50 mM sodium phosphate buffer, pH 8.0, 300 mM NaCl,
250 mM imidazole). The amount of protein in each fraction
was determined using the Bradford assay before immunoblot
analysis.
Protein Bodies (Density Gradient Centrifugation)
The frozen leaf powder was mixed 1:1 (w/v) with extraction
buffer (10 mM Tris-HCl, 0.4 M sucrose, pH 7.5) and incubated
overnight at 4◦C with constant shaking. The homogenate was
passed through two layers of miracloth to remove solid debris
and then loaded on a discontinuous sucrose gradient (3, 2.5, 2,
1.5, and 1 M in 10 mM Tris-HCl, pH 7.5). This preparation
was centrifuged at 30,000 rpm and 4◦C for 3 h in a Beckman
ultracentrifuge (SW 41Ti or SW32TI rotor). After separation,
500-µl fractions were collected for analysis by SDS-PAGE and
immunoblotting.
Protein PAGE and Immunoblot Analysis
Infiltrated leaves (7 DPI) were harvested and ground in liquid
nitrogen to a fine powder. We then extracted 60 mg of leaf
powder in 200 µl buffer K (62.5 mM Tris, pH 7.4, 10%
glycine, 5% 2-mercaptoethanol, 2% SDS, 8 M urea). Ten
microliter of the extract were mixed with loading buffer and
boiled for 10 min before loading. Samples collected from the
density gradient and IMAC procedures were mixed with 5x
loading buffer, boiled at 100◦C for 10 min and separated
by reducing SDS-PAGE (12% polyacrylamide gel, 200 V for
90 min). Gels were stained with Coomassie Blue or transferred
to a nitrocellulose membrane. The membrane was blocked with
5% (w/v) skimmed milk in phosphate buffered saline (PBS)
for 1 h and then incubated with a mouse anti-poly-histidine
antibody (Sigma-Aldrich Chemie GmbH, Germany) at room
temperature for 2 h, diluted 1:10000. The blot was washed three
times in PBS plus 0.05% Tween-20 (PBST) and then incubated
for 1 h with the secondary anti-mouse alkaline phosphatase-
conjugated antibody (diluted 1:5000). The membrane was
washed another three times with PBST and the signal was
detected using the NBT/BCIP system. For quantitation, the
samples were compared to serial dilutions of a His6-tagged
standard protein, and the images were analyzed using BioRad
Image Lab v5.1.
Fluorescence Microscopy
Infiltrated leaves were cut into small pieces with a razor
blade and fixed in 4% (w/v) paraformaldehyde plus 0.5% (v/v)
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) at 4◦C
overnight. For immunolocalization by confocal microscopy,
vibratome sections were mounted on a glass slide, blocked with
5% (w/v) bovine serum albumin (BSA) in 0.1 M phosphate
buffer (pH 7.4) and incubated with a polyclonal antibody
against 27 kD γ-zein. The samples were then incubated
with an AlexaFluorr488-conjugated secondary antibody and
observed under a Leica SP5 confocal laser scanning microscope
(CLSM).
Immunization of Mice
Male BL6 C57/Bacl6J mice (6–8 weeks old) obtained from
Charles River Laboratories, Research Models and Services
were assigned to seven groups (n = 10). Immunization
was carried out by the subcutaneous injection of 150 or
300 ng of H5-zein either with or without Freund’s adjuvant
(1:1) (Difco Laboratories, Detroit, Michigan). For the primary
immunization, complete Freund’s adjuvant was used where
indicated. Booster immunizations consisted of two additional
injections of the same antigen (with or without incomplete
Freund’s adjuvant). As controls, one group received PBS with
Freund’s adjuvant only, and two groups were injected three
times with soluble H5 (15 µg), with or without adjuvant.
After the third immunization, the mice were retro-orbitally
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bled and serum samples were collected for individual testing.
A second set of blood samples was taken 8 weeks after the
primary immunization and the mice were sacrificed immediately
afterward.
The animal experiments were approved by the
Landesverwaltungsamt Sachsen-Anhalt, Halle/Saale,
Referat Verbraucherschutz, Veterinärangelegenheiten and
by the Landkreis Harz, Amt für Veterinärwesen und
Lebensmittelüberwachung, Halberstadt. All animals received
humane care according to the requirements of the German
Animal Welfare Act, §8 Abs. 1.
IgG Quantitation by ELISA
The wells of a flat-bottom microtiter plate were coated with
0.2 µg per well of the antigen (purified recombinant H5 or
zein (Sigma–Aldrich Chemie GmbH, Germany)). Then 100 µl of
diluted serum (1:250 in PBS with 3% BSA) was added to each well
and incubated at room temperature for 1.5 h. Rabbit anti-mouse
IgG alkaline phosphatase-conjugated antibody (diluted 1:2000
in PBST) was used for detection. The IgG titer was determined
by adding immune serum samples as serial dilutions starting at
1:1000. Curve fitting by five-parameter logistic regression was
used to calculate the endpoint titer for each mouse. End-point
titers were determined as the reciprocal highest serum dilutions
that produced mean optical density values two-fold greater than
the geometric mean of those from the negative control (injected
with PBS) sera. The statistical significance was determined using
Student’s t-test (∗∗p < 0.01; ∗p < 0.1).
Selected ELISA experiments were carried out using
recombinant H5 purified via an additional size exclusion
chromatography step. The same results were obtained, indicating
that the H5 preparation purified via IMAC was sufficiently
pure for coating, and did not contain significant amounts of
immunoreactive impurities.
Hemagglutination Inhibition (HI) Test
HI tests were carried out as described by Phan et al. (2013).
Briefly, a 25-µl aliquot of murine serum was mixed with 25 µl
PBS and added to the first well of a V-bottom microtiter plate.
Twofold serial dilutions were prepared across the row of 12
wells. Aliquots (25 µl) containing 4HAU of inactivated virus
[A/swan/Germany/R65/2006(H5N1)] were added to each well
and incubated for 30 min at room temperature. We then pipetted
25 µl of a 1% red blood cells (RBCs) suspension into each
well and the plate was again incubated for 30 min at room
temperature. The HI titer was defined as the reciprocal of the
highest serum dilution that achieved the complete inhibition of
hemagglutination.
RESULTS
Hemagglutinin-Zein Fusions form PBs in
N. benthamiana Leaves
Expression vector “H5-Zein” containing the sequence
corresponding to the H5 ectodomain of hemagglutinin,
FIGURE 1 | Production and isolation of H5-zein and H5. (A) Immunoblot
analysis of a leaf extract containing H5-zein. (B) Immunoblot of H5-zein
samples following the sucrose density gradient separation of leaf
homogenates. Lanes 1–5: Selected samples from different density steps
along the gradient are shown (lane 1: sample from the top of the gradient;
lane 5: pellet. 4G and 5G are the same fractions as 4 and 5, but obtained
from a different experiment). An antibody specific for the His6 tag was used for
detection. (C) H5 after IMAC purification (3 µg were leaded on the gel and
stained with Coomassie). wt, wild type; L, molecular weight ladder in kDa.
fused to amino acids 4–93 of the mature 27 kD γ-zein protein,
was introduced into N. benthamiana leaves by agroinfiltration.
Immunoblot analysis of extracts from the infiltrated leaves
7 DPI revealed the presence of a band corresponding to the
fusion protein (Figure 1A). The higher than predicted molecular
mass probably reflected the glycosylation of H5, as previously
reported (Phan et al., 2014). The fusion of H5 to zein resulted
in the formation of PBs, whose presence was confirmed by
immunofluorescence microscopy. All labeling was concentrated
in the PBs, whereas no signal was detected in the ER lumen
or in the apoplast (Figure 2). This result was confirmed by
the density step gradient centrifugation of leaf homogenates
(Figure 1B). The gradient fractions were collected and tested by
immunoblot analysis. No recombinant fusion protein was found
in fractions from the top of the gradient, a small amount was
present in the highest density fractions, and the majority of the
fusion protein was found in the pellet (Figure 1B), similar to
results reported with another zein fusion protein that forms PBs
(Whitehead et al., 2014). Sucrose was removed by pooling the
selected fractions and resuspending them in 10 mM Tris (pH 7.5)
before centrifuging them under the same conditions as above.
The supernatant was removed and the pellet was re-suspended
in sterile PBS. The protein suspension was stored at –20◦C
prior to the immunization experiments. A total of ∼120 µg
H5-zein was recovered from 300 g of fresh infiltrated leaves.
Soluble H5 lacking the zein fusion was expressed as a control
and purified by IMAC as previously described (Phan et al.,
2013). We recovered 1 mg of H5 from 500 g of fresh infiltrated
leaves, and this was used as a positive control for immunization
(Figure 1C).
H5-Zein PBs Elicit an Immune Response
in Mice
The H5-zein protein body suspension and the soluble H5
antigen were each used to immunize mice (Figure 3). The
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FIGURE 2 | Immunolocalization of H5-zein in N. benthamiana leaves by
confocal microscopy. (A) Abundant H5-zein protein bodies (PBs) can be
observed in mesophyll cells (arrows). (B) H5-zein PBs are 1–2 µm in diameter
and can be found in the cytoplasm between the chloroplasts (arrows). The left
panel shows the detection of the fusion protein. The middle panel shows
autofluorescence of the chloroplasts. The right panel shows the overlay
pictures. Abbreviations: v, vacuole. Bars = 10 µm.
mice were allocated to seven groups (n = 10 per group) and
immunization was carried out by the subcutaneous injection
of 150 or 300 ng of H5-zein either with or without Freund’s
adjuvant. This low dosage of H5-zein bodies was chosen to
confirm the hypothesis that particulate antigens are effective in
small amounts. As controls, two groups were injected three times
with soluble H5 (15 µg, a dose previously confirmed to provoke
a strong humoral immune response), one with and one without
adjuvant.
The plant-derived H5-zein protein body suspension was
shown to elicit an IgG response in 100% of the animals, even
at low doses. Interestingly, the addition of an adjuvant to the
H5-zein bodies did not cause a significantly stronger immune
response (Figure 3, groups 1 vs. 3 and 2 vs. 4), whereas the
adjuvant had a significant impact in the control groups receiving
soluble H5 (Figure 3, groups 5 vs. 6).
The Zein Fusion Component is Only
Weakly Immunogenic but has a
Significant Adjuvant Activity
To confirm the observations summarized above, we carried
out an in-depth comparison of IgG titers of groups 3, 5,
and 6. The IgG response elicited by H5-zein without adjuvant
(group 3) was comparable to that achieved by injecting
soluble H5 combined with an adjuvant (group 5). In contrast,
the administration of soluble H5 without adjuvant elicited a
minimal IgG response (Figure 4A). This suggested that the zein
component and/or the particulate nature of the protein body act
as an adjuvant.
To determine whether the zein portion fused to H5 has
intrinsic immunogenic properties, we investigated the IgG
response directed against zein by comparing the IgG response
in groups 1 (H5-zein with adjuvant), 3 (H5-zein without
FIGURE 3 | Immunization timeline and IgG responses in the seven treatment groups. (A) All mice were injected with a primary dose of H5-zein (6 µg/ml) or
H5 (0.6 mg/ml), both in sterile PBS, with or without Freund’s complete adjuvant. For the second and third injections, the adjuvant was switched to Freund’s
incomplete adjuvant. (B) ELISA analysis of the anti-H5 IgG response following the third immunization. A single dot represents the ELISA result from a single serum
sample. Each treatment group comprised 10 mice.
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FIGURE 4 | Serum IgG response against (A) H5 and (B) zein. Data represent the median endpoint titer per group, whereas the lower and upper ends of the
error bars represent the first and third quartiles, respectively. (A) Statistical analysis to compare group 3 (H5-zein without adjuvant) and group 5 (H5 with adjuvant) vs.
group 6 (H5 without adjuvant). (B) Statistical analysis to compare group 1 (H5-zein with adjuvant) and group 3 (H5-zein without adjuvant) vs. group 5 (H5 with
adjuvant). Each treatment group comprised 10 mice. Statistical significance was determined by Student’s t-test (∗∗p < 0.01; ∗p < 0.1; no asterisk indicates
p > 0.1).
adjuvant), and 5 (soluble H5 with adjuvant). Although we
generally detected low IgG titers, 30% of the animals in groups
1 and 3 showed a clearly detectable IgG response against zein
(Figure 4B). Overall the immune response in the treatment
groups was not significantly different to that of the control group
(p > 0.1).
HI Antibody Titers are Insignificant
All mice vaccinated with H5-zein PBs showed an immunological
response so we carried out HI tests on the serum from
each mouse to determine whether the induced antibodies
were potentially capable of neutralizing the virus. Because
of the unavailability of the A/Hatay/2004(H5N1) virus in
an inactivated form, the heterologous inactivated virus strain
A/swan/Germany/R65/2006(H5N1) was used for the HI assay.
The deduced hemagglutinin amino acid sequence similarity
of both strains is 96%, and it was previously shown that
HI titres against inactivated virus A/swan/Germany/R65/2006
(H5N1) could be measured in sera from mice vaccinated with
trimeric HA derived from the HA sequence corresponding to
the A/Hatay/2004(H5N1) virus (Phan et al., 2013). The HI assay
results indicated that the HI antibody titers were either below
or marginally above the detection limit in all treatment groups
(Table 1).
TABLE 1 | HI titers against inactivated virus
[A/swan/Germany/R65/2006(H5N1)].
Treatment group Geometric mean titer
1 (H5-zein + adjuvant) 6,06
3 (H5-zein) 4,29
6 (H5) 3,4
7 (PBS) 7,46
DISCUSSION
The expression of recombinant proteins in plants is an attractive
strategy reflecting the versatility, safety, scalability, and economy
of plant-based production platforms (Rybicki et al., 2013; Stoger
et al., 2014). Plants also offer the possibility to accumulate
recombinant pharmaceutical proteins within endogenous or
ectopic protein storage organelles, which can either be derived
directly from the ER or represent protein storage vacuoles (Khan
et al., 2012). Here, we successfully induced the formation of
ectopic PBs by fusing the H5 ectodomain of hemagglutinin to the
N-terminal sequence of γ-zein. Previous studies have shown that
the biogenesis of PBs by zein is influenced by the fusion partner,
and that not all fusion proteins support the efficient formation
of PBs. For example, phaseolin induces the efficient formation
of zeolin PBs when fused to the N-terminal sequence of γ-zein
(Mainieri et al., 2004). However, PBs were not formed when the
Human immunodeficiency virus Nef antigen was fused to the
same γ-zein sequence, but protein body formation was possible
again when Nef was fused to the entire chimeric protein zeolin
(de Virgilio et al., 2008).
The induction of H5-containing protein aggregates in plants
has also been achieved by fusing the antigen to hydrophobin and
ELPs (Phan et al., 2014). The H5-ELP PBs were approximately
800 nm in diameter whereas the H5-hydrophobin PBs were
substantially smaller, with an average diameter of 250 nm. The
H5-zein PBs reported herein were larger, with a diameter of
1–2 µm, which is similar to the average size of endogenous
zein bodies found in maize endosperm (Lending and Larkins,
1989). In contrast to the H5-ELP and H5-hydrophobin PBs, H5-
zein formed high density structures that were insoluble in non-
reducing buffers, whereas H5-ELP and H5-hydrophobin fusion
proteins could be extracted in 50 mM Tris, pH 8.0 (Phan et al.,
2014).
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The H5-zein bodies described herein were used as a delivery
vehicle for a model vaccine antigen. IgG responses were
elicited in all mice immunized with H5-zein but HI assays
indicated the absence of neutralizing antibodies. Our results
agree with previous parenteral immunization studies using
monomeric hemagglutinin fused to ELP, which, in contrast
to trimeric hemagglutinin, also did not induce neutralizing
antibodies (Phan et al., 2013). Although the formation of
PBs involves multiple cross-linking via intermolecular disulfide
bonds, this type of multimerization may not be sufficient to
support the specific oligomerization state that appears to be
required for the formation of specific native epitopes that may
confer a seroprotective immune response. Proper trimerization
may be required to complete the folding of hemagglutinin
monomers and to induce conformational effects necessary for
full antigenicity and the induction of neutralizing antibodies
(Magadan et al., 2013). The introduction of a trimerization signal
in addition to the assembly sequence may therefore be beneficial,
as reported for H5-ELP fusions (Phan et al., 2013).
One remarkable outcome of our experiments was that a
comparable immune response was elicited in all mice despite
the H5-zein concentration being 100 times lower than the
concentration of soluble H5 in the control group, which
was administered with a strong adjuvant. Interestingly, the
administration of an adjuvant together with the H5-zein bodies
did not promote a stronger immune response, suggesting that
the addition of the zein portion itself mediates an adjuvant
effect. This agrees with Whitehead et al. (Whitehead et al.,
2014), who recently reported that the immunogenicity of a
recombinant antigen was increased in the presence of Zerar,
an assembly sequence that is very similar to the N-terminal
part of γ-zein (Torrent et al., 2009b), and the immunogenicity
of the fusion protein could not be enhanced further by
the inclusion of Freund’s adjuvant. Similarly, the injection of
synthetic zein microspheres that were loaded with ovalbumin
resulted in higher IgG responses than the ‘free’ soluble protein
(Hurtado-Lopez and Murdan, 2006a). This strongly supports
the hypothesis that the zein N-terminal portion possesses
intrinsic adjuvant activity, although we cannot exclude the
possibility that the observed adjuvant effect was mediated
by another component of the PBs. Joseph et al. reported
that zein-induced PBs isolated from leaves contain additional
proteins that are trapped during biogenesis (Joseph et al.,
2012).
An adjuvant effect conferred by a polymer-forming protein
domain is not unexpected, given its similarity to the strategy of
attaching a carrier protein such as albumin or keyhole limpet
hemocyanin to antigens with poor immunogenicity (Harris and
Markl, 1999). By definition, an adjuvant is characterized by its
ability to enhance the immunogenic efficacy of antigens in the
same formulation. This can be achieved by increasing the half-
life of an antigen, improving antigen delivery to its effector
sites, or providing immunostimulatory signals to enhance
the immune response. The observed adjuvant effect of zein
particles may reflect one or more of several relevant properties.
First, hydrophobic synthetic block copolymers have been
shown to confer stronger adjuvant properties than hydrophilic
polymers (Newman et al., 1998; Hunter, 2002). Accordingly,
the N-terminal part of γ-zein is partially hydrophobic, favoring
intermolecular and membrane interactions (Kogan et al., 2002).
It has also been reported that particulate antigens are transported
more efficiently to murine splenic follicular dendritic cells
in vivo in the absence of prior immunity, making them
more immunogenic than soluble antigens (Link et al., 2012).
This may also be reflected by the superior immunogenicity
of hemagglutinin-containing virus-like particles compared to
soluble hemagglutinin, even in the absence of an adjuvant
(Shoji et al., 2015). Also, repetitive antigen display, structural,
or molecular mimicry of the virus, particle-size dependent tissue
penetration and trafficking to lymphatics and Toll-like receptor
activation are possible mechanisms. In repetitive antigen display
the spatial organization of the antigens on the particle surface
facilitates B-cell receptor (antibody) co-aggregation, triggering
and activation. This can support the production of long-
lived high-affinity neutralizing antibodies (Smith et al., 2013).
Plant-derived PBs might also provide a specific spatial antigen
organization favoring a successful repetitive antigen display.
Alternatively, increased half life and stability of the zein fusions in
the serum in vivo might be responsible for the enhanced immune
response. The half-life of the antigen is likely to be extended
due to encapsulation in the protein body. Indeed, pharmaceutical
preparations encapsulated in zein particles in vitro remained in
the blood for at least 24 h following intravenous delivery (Lai
and Guo, 2011). Interestingly, the fusion of hemagglutinin to ELP
repeats did not seem to increase immunogenicity although the
propensity to form protein aggregates was confirmed in planta
(Phan et al., 2013, 2014).
Zein has several favorable general characteristics as an
adjuvant, i.e., it is stable at ambient temperatures and yet
it is biodegradable, encouraging its use as a biopolymer
for the coating and encapsulation of recombinant proteins
such as erythropoietin (Bernstein et al., 1993). However, the
potential immunogenic properties of zein must be taken into
account (Hurtado-Lopez and Murdan, 2006a; Whitehead et al.,
2014). We detected an immune response directed against
γ-zein although the response was much weaker than that
directed against H5, and when compared to the control
group administered with H5 alone, the difference between
the groups was not statistically significant. However, 30% of
the mice injected with H5-zein showed an immune response
above background levels. A significant immune response
against the zein-like sequence Zera has been reported by
(Whitehead et al., 2014), warranting further studies to assess the
suitability of zein bodies as drug delivery vehicles for parenteral
administration. Animal studies involving the injection of zein-
coated erythropoietin (Bernstein et al., 1993) and ivermicin
(Gong et al., 2011) did not indicate any adverse effects.
Other storage proteins, including the wheat storage protein
gliadin, have also been used as coatings to prepare various
proteins and pharmaceuticals in vitro. GliSODinr for example
is an oral treatment for oxidative stress, in which superoxide
dismutase (SOD) is coated with gliadin (Cloarec et al., 2007).
Although gliadin protects SOD from digestion, this storage
protein is also linked to the autoimmune disorder celiac disease
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(Chaptal, 1957). Even so, this product has received market
approval for human use.
CONCLUSION
Zein and similar plant storage proteins have long been
investigated as carriers for pharmaceuticals including
recombinant proteins. The direct encapsulation of
pharmaceutical proteins in the production host is a simple
approach that is less expensive than the production of synthetic
microparticles. Our case study using a model vaccine antigen
indicates that zein-induced PBs can be used as vaccine delivery
vehicles that benefit from a value-added adjuvant effect, whereas
the intrinsic immunogenicity of the zein component is low.
The insertion of a trimerization signal fused to H5 will be
tested to determine whether this leads to the assembly of
structures that can elicit neutralizing antibodies against H5.
It will also be of value to develop the in planta protein
body encapsulation strategy for the production and delivery
of further antigens, including candidates intended for oral
application.
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